OncLive TV

Dr. Ailawadhi on Patient Considerations for BTK Inhibitors in Waldenström Macroglobulinemia

September 3rd 2021

Sikander Ailawadhi, MD, discusses patient considerations for BTK inhibitors in Waldenström macroglobulinemia.

Dr. Cohen on Tailoring Treatment to Individual Subtypes in CRC

September 2nd 2021

Stacey A. Cohen, MD, discusses tailoring treatment approaches to individual subtypes in colorectal cancer.

Dr. Chiorean on the Role of Molecular Testing in Pancreatic Cancer

September 2nd 2021

E. Gabriela Chiorean, MD, discusses the role of molecular testing in pancreatic cancer.

Dr. Rampal on the Importance of Genomic Testing in Myelofibrosis

September 2nd 2021

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

Dr. Patil on ADAURA Data with Osimertinib in NSCLC

September 2nd 2021

Pradnya D. Patil, MD, FACP, discusses data from the phase 3 ADAURA trial in patients with EGFR-mutated non–small cell lung cancer.

Dr. Hurvitz on Outcomes With Sacituzumab Govitecan in TNBC

September 1st 2021

Sara A. Hurvitz, MD, discusses outcomes with sacituzumab govitecan-hziy in patients with metastatic triple-negative breast cancer.

Dr. Garg on the Need for Novel Imaging Techniques in nmCRPC

September 1st 2021

Natasha Garg, DO, discusses the utility of novel imaging techniques in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Wang on the Final Results of the ACE-LY-004 Trial in MCL

September 1st 2021

Michael Wang, MD, discusses the use of acalabrutinib in the phase 2 ACE-LY-004 trial in mantle cell lymphoma.

Dr. Stevenson on the Importance of Early Screening in Lung Cancer

September 1st 2021

James Stevenson, MD, discusses the importance of early screening in lung cancer.

Dr. Riedell on the Importance of Identifying Early Relapse High-Risk MCL

September 1st 2021

Peter Riedell, MD, discusses the importance of identifying early relapse in patients with high-risk mantle cell lymphoma.

Dr. Atallah on the Prognostic Role of Undetectable MRD in CLL

August 31st 2021

Ehab L. Atallah, MD, discusses the prognostic role of undetectable minimal residual disease in chronic lymphocytic leukemia.

Dr. Murthy on the Potential Benefits of Treatment De-Escalation in Ph+ B-ALL

August 31st 2021

Guru Subramanian Guru Murthy, MD, MS, discusses the potential benefits of treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Dr. Mauro on the Risks of Disease Progression in Myelofibrosis

August 31st 2021

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Dr. Ward on the Benefits of Delaying Salvage Therapy in Prostate Cancer

August 31st 2021

Matthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.

Dr. Martin on Key Advances in Multiple Myeloma

August 31st 2021

Thomas G. Martin, MD, discusses recent key advances in multiple myeloma.

Dr. Lyou on Key Takeaways from the ENZAMET Trial in Metastatic Prostate Cancer

August 31st 2021

Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.

Dr. Wenham on the Potential for Immunotherapy in Ovarian Cancer

August 31st 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses the potential for immunotherapy in ovarian cancer.

Dr. Dorff on Biomarkers of Response to PARP Inhibitors in Prostate Cancer

August 30th 2021

Tanya B. Dorff, MD, discusses biomarkers of response to PARP inhibitors under investigation in prostate cancer.

Dr. Lyou on the Efficacy of ADT Plus Docetaxel in High-Volume mHSPC

August 30th 2021

Yung Lyou, MD, PhD, discusses the efficacy of androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Dr. Zhang on the State of Risk Stratification in mCRPC

August 30th 2021

Jingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.